Answers are grounded in this paper and cite their sources.
Maximizing the efficacy of IBD-directed therapies while minimizing their toxicity remains the principal objective in developing management strategies for all IBD patients. Maintaining good quality of life and adherence to therapies are also important considerations. Moreover, maximizing both physical and psychosocial growth during the most dynamic phase of a child's development truly highlights the importance of optimizing the management of children with IBD. An optimal treatment strategy requires the implementation of a single medication or combination thereof that both induce a state of remission and maintain the disease in a quiescent state long-term with minimal safety concerns. To date no single therapy meets the criteria of “the ideal IBD therapy”. Corticosteroids remain the mainstay for effective induction therapies in the short term for patients with moderate to severe disease activity given their rapid onset of action and proven efficacy. However the unacceptable safety profile, in particular its negative effect on growth in children and reported natural history of steroid resistance and dependence renders corticosteroids an undesirable maintenance therapy (1,2). A pivotal study by Markowitz et al demonstrated that the combination of prednisone and 6-mercaptopurine (6-MP) in newly diagnosed pediatric Crohn's disease was very effective in both the induction and maintenance of disease remission (3). The steroid sparing advantage of this combination regime is what exemplifies this management strategy as an important part of the therapeutic approach to pediatric IBD patients. Despite a recent increase in the use of thiopurines, there still remains a discrepancy between the proportion of patients who need this therapy and the proportion of patients who are actually receiving it. Delayed onset of action and concerns regarding both short and long-term toxicity are the most common explanations for this inconsistency. Thus, hastening the time to response while maximizing the frequency of response would significantly improve the overall benefit of thiopurines. Similarly the identification of those patients who are unlikely to benefit from these therapies and/or are at increased risk for toxicity would certainly improve therapeutic outcomes. The observed differences in thiopurine response, referring to both safety and efficacy heterogeneity, among IBD patients can be attributed in part to the inherited differences affecting drug metabolism among individuals treated with these therapies. The immunosuppressive and cytotoxic effects of thiopurines are mediated by way of the conversion of 6-MP to the 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP) nucleotide metabolites. The relative proportion of 6-TG and 6-MMP produced is influenced by the level of thiopurine methyltransferase (TPMT) enzyme activity expressed by a given individual. Population based studies have demonstrated that TPMT activity is inherited as an autosomal co dominant trait. The frequency distribution of the TPMT polymorphisms reveals that 1 in 300 (0.3%) individuals have low to absent enzyme activity (homozygous TPMTL), 11% have intermediate (heterozygous TPMTH/TPMTL) and 89% have normal to high levels of activity (homozygous/wild type TPMTH) (4). TPMT methylation of 6-MP results in the formation of 6-MMP and directly competes with the enzymatic pathways responsible for 6-TG production resulting in an inverse relationship between TPMT and 6-TG. Studies have shown that high 6-TG levels correlate with clinical remission in both adult and pediatric IBD patients (5,–7). Moreover, response was found to be optimized at 6-TG levels above 235 pmol/8 ×108 RBC (OR; 5.0 (95% CI, 2.6-9.7; p<0.001) (5). Similar findings have been reported among leukemia patients where target drug levels of 6-TG correlated with improved disease free-survival (8,9). However, the therapeutic window of thiopurines narrows as the risk of leukopenia increases. A large proportion of leukopenic events can be explained by high 6-TG levels given the inverse correlation between 6-TG and the white blood cell count (10,–11). Genetic variability of TPMT enzymatic activity is the most important influence on the quantity of 6-TG produced. Given the negative relationship between TPMT and 6-TG, patients with intermediate to low TPMT activity accumulate intermediate to high concentrations of 6-TG (5,12). Thus, the knowledge of an individual's TPMT enzyme prior to initiation of therapy plays a crucial role in the safe administration of thiopurines. TPMT activity does not appear to predict which patients will develop an allergic or non-dose dependent adverse event to thiopurines, however, there is a lot to be said for the ability to predict which patients are at risk for developing a dose dependent effect on the bone marrow manifested most commonly as leukopenia. Patients with low to absent TPMT activity (1/300) are at highest risk for potentially fatal bone marrow complications and are generally not considered good candidates for thiopurines (13,14). These patients can be safely identified by a single TPMT measurement; either genotype or phenotype, prior to starting therapy and alternative immunomodulators can be implemented in a timely manner. Granted that most patients receiving thiopurines can safely initiate therapy at a sub-therapeutic dose, there still remains a proportion of patients with reduced TPMT activity that are at risk for bone marrow suppression even when receiving standard doses of thiopurines and may require early discontinuation (15). These intermediate TPMT producers can ultimately receive thiopurines but careful initial dosing (approximately 50% of standard dose) should be considered and dose escalation should take place with diligent monitoring of complete blood counts to ensure the safe administration of these therapies (16). For the majority of patients who are normal to high TPMT metabolizers, clinicians can safely administer what is considered an effective dose of 6-MP (1–1.5 mg/kg/day) and AZA (2.0–2.5 mg/kg/day) (3,17). Thus, the a priori knowledge of at risk patients can guide therapeutic decision-making and dosing strategies for patients in whom thiopurines are being considered. Individualizing patient dosing based on TPMT activity certainly offers a safety advantage for thiopurine therapy. The overall treatment objective, however, is to hasten time to response and maximize the probability of achieving and maintaining response. Pushing the dose until a patient experiences leukopenia has been suggested as a mechanism to achieve these therapeutic goals (18). However with the introduction of therapeutic drug monitoring into the clinical practice of IBD patients, leukopenia is no longer a necessary or desirable endpoint given the infectious complications that can result. Reports among adults and children with IBD have shown that the frequency of response to thiopurines positively correlates with the level of 6-TG as measured in the red blood cell (RBC) (5,6). As noted above, response is optimized at 6-TG levels > 235 pmol/8 × 108 RBC). Unlike 6-TG, a positive correlation between 6-MMP levels and clinical response has not been demonstrated. By contrast, an elevated 6-MMP level, exceeding 5700 pmol/8 X 108 RBC, can be associated with a higher risk of hepatotoxicity, typically manifesting as transaminitis (5,19). Inadequate dose remains the most common explanation for thiopurine failure. Although the presence of leukopenia may suggest maximum dose, metabolite monitoring has broadened our understanding of the biochemical nature of the variability of thiopurine responses among IBD patients. Given what we now know about the correlation between efficacy and 6-TG levels, inadequate dose may be more appropriately replaced by inadequate or sub optimal 6-TG levels as being the most common explanation for failure. Based on the underlying explanation for lack of therapeutic benefit, patients can be identified based on their metabolite profile. For patients in whom a sub-therapeutic dose in being administered, both the 6-TG and 6-MMP levels are present but low, whereas in patients who are not adhering to their treatment plan, neither level is detectable. Adherence to medications remains a very real challenge in caring for children with IBD, adolescents in particular, and thus a mechanism of identifying those patients early will help improve outcomes. 6-TG levels tend to stabilize 2–4 weeks after initiating the drug or after a dose change such that monitoring should take place 3–6 weeks after initiation or after a dose adjustment. By doing the first drug level after just 1 month of therapy, this early metabolite profile can help clinicians gauge the next and perhaps most important stage in thiopurine management. If the 6-TG level is above 235 and the 6-MMP level is not associated with elevations in transaminases, then the likelihood of response is significantly elevated and dose adjustments are not necessary. Patients, whose 6-TG levels are above 450, should be closely monitored for leukopenia and a slight dose decrease may be prudent. If both levels were low, despite TPMT appropriate initial doses, then dose escalation would be appropriate as the next step in achieving therapeutic 6-TG levels and hence optimizing response. Studies have shown that most patients with low 6-TG levels can improve the probability of response by increasing their dose and in turn increasing their 6-TG levels (7). However, not all patients are able to metabolize thiopurines in this favorable manner such that a proportion of IBD patients are unable to produce therapeutic 6-TG levels despite dose escalation (19). These “6-MP resistant” patients are biochemically characterized by a low 6-TG and high 6-MMP level. Not only do these patients respond less favorably to thiopurines, they are also at risk for hepatoxicity and typically this limits dose escalation. The recognition of these patients early on in the course of treatment can hasten the identification of patients who would benefit from alternate long-term immunomodulators and pharmacological approaches. The literature supports the role of TPMT screening and 6-MP metabolite monitoring in the management of IBD patients receiving thiopurines. Pharmacogenetics, the study of how inherited factors affect drug response, has now found its way into the clinical practice of IBD patients. By understanding the inter-individual difference in drug metabolism and how it affects therapeutic response, clinicians caring for both children and adults with IBD can optimize therapeutic efficacy while reducing risk.
No takes yet. Share an insight, caveat, or question.
Marla C. Dubinsky (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: